MARKET

ITRM

ITRM

Iterum Therapeutics plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.280
-0.270
-7.61%
Closed 16:00 12/06 EST
OPEN
3.550
PREV CLOSE
3.550
HIGH
4.135
LOW
3.180
VOLUME
87.12K
TURNOVER
--
52 WEEK HIGH
9.30
52 WEEK LOW
1.680
MARKET CAP
42.98M
P/E (TTM)
-0.4611
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ITRM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ITRM News

  • CPST, CRC, RVNC and ORMP among notable midday movers
  • Seeking Alpha - Article.2d ago
  • CBL, CARA, VRAY and BOLD among midday movers
  • Seeking Alpha - Article.3d ago
  • Is Iterum Therapeutics plc (ITRM) Going To Burn These Hedge Funds ?
  • Insider Monkey.6d ago
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About ITRM

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The Company is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The Company is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. It is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. It has demonstrated potent in vitro activity against all genera of Enterobacteriacease, in anaerobes such as Bacteroides, Prevotella, Porphyromonas, Fusobacterium and Peptostreptococcus, gram-positive organisms including methicillin-susceptible staphylococci, Streptococcus pyogenes and Streptococcus pneumonia.
More

Webull offers Iterum Therapeutics PLC (ITRM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.